Article

Capacity for compensatory cyclin D2 response confers trametinib resistance in canine mucosal melanoma

2025-04-26

Abstract excerpt

<h4>Background/objective</h4> Mucosal melanoma (MM) is a poorly responsive, rare and aggressive subtype with paucity of targetable recurrent driver mutations, although Ras/MAPK and PI3K/AKT/mTOR signaling pathway activations are common. Eventual tumor evasion of targeted therapy continues to limit treatment success. Adequate models are necessary to address therapeutic resistance. The relatively greater incidence...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc09ce71-2d50-5d6e-98ff-61ca45e13f0b
DOI: 10.1101/2025.04.24.650512

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Capacity for compensatory cyclin D2 response confers trametinib resistance in canine mucosal melanomaDOI 10.1101/2025.04.24.650512Read

Somatic inactivating <i>PTPRJ</i> mutations and dysregulated pathways identified in canine melanoma by integrated comparative genomic analysisSemantic proximity Read

Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.Semantic proximity Read

Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanomaSemantic proximity Read

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.Semantic proximity Read

The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects.Semantic proximity Read

The caninized anti-canine PD-1 monoclonal antibody in canine oral malignant melanoma: Efficacy and exploratory biomarker analysisSemantic proximity Read

Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion AbilitiesSemantic proximity Read

PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine MelanomaSemantic proximity Read

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read

IQGAP1 is an oncogenic target in canine melanoma.Semantic proximity Read

Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness.Semantic proximity Read